Please login to the form below

Not currently logged in
Email:
Password:

etoricoxib

This page shows the latest etoricoxib news and features for those working in and with pharma, biotech and healthcare.

Grunenthal to market MSD’s pain drug

Grunenthal to market MSD’s pain drug

Grünenthal has agreed a deal with MSD to market its pain medicine Arcoxia (etoricoxib) in several major European markets. ... In these countries, Grünenthal will hold exclusive promotion and distribution rights to the COX-2 inhibitor etoricoxib under

Latest news

  • EMEA counsels COX-2 action

    With regard to other COX-2 inhibitor pain relievers available within the EU, which include celecoxib (Celebrex; Pfizer), etoricoxib (Arcoxia; Merck &Co), and parecoxib (Dynastat; Pharmacia), the EMEA affirmed that the

  • Merck lambasted over semi-revelation

    The trial, which spread itself across 38 countries, saw Arcoxia (etoricoxib) pitted head to head against diclofenac, an older non-steroidal anti-inflammatory drug (NSAID) already widely prescribed in arthritis communities.

  • RA market to flourish

    Meanwhile, approval of Merck's Arcoxia (etoricoxib) for RA has been delayed in the US pending further safety and efficacy data, although it is already launched in the UK and several

  • News in brief, May 02, 2007

    Regulatory news. FDA rejects Vioxx replacement. The FDA has rejected Merck &Co's request to market Arcoxia (etoricoxib), a replacement for its withdrawn arthritis drug, Vioxx (rofecoxib). ... Wolfe noted that trial data presented by Merck on

  • News in brief, April 11, 2007

    The announcement will not please US pharmaceutical company, Merck &Co, which is waiting for an FDA ruling on its Vioxx (rofecoxib) replacement, Arcoxia (etoricoxib).

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics